Highbridge Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Highbridge Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-30,000	Closed	-$1.53M	–	1251
2018 Q1	$1.53M	Buy	+30,000	New	+$1.51M	0.02%	468
2016 Q3	–	Sell	-7,304	Closed	-$357K	–	1623
2016 Q2	$357K	Buy	+7,304	New	+$472K	0.01%	985
2015 Q2	–	Sell	-34,311	Closed	-$2.13M	–	1618
2015 Q1	$2.13M	Buy	34,311 +5,019	+17%	+$279K	0.03%	519
2014 Q4	$1.28M	Buy	+29,292	New	+$1.34M	0.02%	578

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Highbridge Capital Management's RARE Position: Q2 2018 in Review

Highbridge Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2018, closing a stake of 30,000 shares — an estimated $1.53M sold.

Highbridge Capital Management first reported a position in RARE in Q4 2014 and held it in 4 quarters. The position peaked at $2.13M in Q1 2015. 158 funds tracked by Wall St. Rank hold RARE as of Q2 2018.

Highbridge Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 30,000 Ultragenyx Pharmaceutical shares in Q2 2018, an estimated $1.53M.
Highbridge Capital Management first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and held it in 4 quarters.
Highbridge Capital Management's Ultragenyx Pharmaceutical position peaked at $2.13M in Q1 2015.
158 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.